<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665921</url>
  </required_header>
  <id_info>
    <org_study_id>SGNSTNV-001</org_study_id>
    <nct_id>NCT04665921</nct_id>
  </id_info>
  <brief_title>A Study of SGN-STNV in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of SGN-STNV in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will look at a drug called SGN-STNV to find out whether it is safe for patients&#xD;
      with solid tumors. It will study SGN-STNV to find out what its side effects are. A side&#xD;
      effect is anything the drug does besides treating cancer. It will also study how well&#xD;
      SGN-STNV works to treat solid tumors.&#xD;
&#xD;
      The study will have two parts. Part A of the study will find out how much SGN-STNV should be&#xD;
      given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is&#xD;
      and if it works to treat certain types of solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include dose escalation (Part A) and dose expansion (Part B), with multiple&#xD;
      disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will be&#xD;
      gated based on data generated from other expansion cohorts and will require additional&#xD;
      biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts&#xD;
      and 1 biology expansion cohort may be activated by the sponsor in consultation with the&#xD;
      Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with&#xD;
      selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in&#xD;
      Part B will be at or below the maximum tolerated dose and/or the recommended dose determined&#xD;
      in Part A. The recommended dose and/or schedule may differ between cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>To be summarized using descriptive statistics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as assessed by the investigator per RECIST v1.1</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>ORR is defined as the proportion of subjects achieving a partial response (PR) or complete response (CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>PFS is defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>OS is defined as the time from the start of any study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (DOR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>Pharmacokinetic (PK) endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>PK endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antidrug antibodies (ADA)</measure>
    <time_frame>Through 30-37 days following last dose of SGN-STNV; up to approximately 3 years</time_frame>
    <description>Immunogenicity endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <condition>HER2 Negative Breast Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Esophageal Neoplasms</condition>
  <condition>Gastroesophageal Junction Carcinoma</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Exocrine Pancreatic Adenocarcinoma</condition>
  <condition>Appendiceal Adenocarcinoma</condition>
  <condition>Pseudomyxoma Peritonei</condition>
  <arm_group>
    <arm_group_label>SGN-STNV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-STNV monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-STNV</intervention_name>
    <description>Given into the vein (IV; intravenously)</description>
    <arm_group_label>SGN-STNV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease indication&#xD;
&#xD;
               -  Must have disease that is relapsed or refractory or be intolerant to&#xD;
                  standard-of-care therapies and should have no appropriate standard-of-care&#xD;
                  therapeutic option.&#xD;
&#xD;
                    -  Non-small cell lung cancer (NSCLC)&#xD;
&#xD;
                    -  HER2 negative breast cancer&#xD;
&#xD;
                    -  Ovarian cancer&#xD;
&#xD;
                    -  Cervical cancer&#xD;
&#xD;
                    -  Endometrial cancer&#xD;
&#xD;
                    -  Esophageal cancer&#xD;
&#xD;
                    -  Gastric cancer and GEJ carcinoma&#xD;
&#xD;
                    -  Colorectal cancer&#xD;
&#xD;
                    -  Exocrine pancreatic adenocarcinoma&#xD;
&#xD;
                    -  Appendiceal adenocarcinoma and pseudomyxoma peritonei of unknown origin&#xD;
&#xD;
          -  Participants enrolled in the following study parts should have a tumor site accessible&#xD;
             for biopsy and agree to biopsy as follows:&#xD;
&#xD;
               -  Disease-specific expansion cohorts, participant 13 onwards: pretreatment biopsy&#xD;
&#xD;
               -  Biology expansion cohort: pretreatment biopsy and additional on-treatment biopsy&#xD;
                  during Cycle 1&#xD;
&#xD;
          -  Measurable disease per the Response Evaluation Criteria in Solid Tumors Version 1.1&#xD;
             (RECIST v1.1) at baseline&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1&#xD;
&#xD;
          -  Adequate renal, hepatic, and hematologic function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of another malignancy within 3 years before the first dose of study drug, or&#xD;
             any evidence of residual disease from a previously diagnosed malignancy.&#xD;
&#xD;
          -  Known active central nervous system metastases&#xD;
&#xD;
          -  Carcinomatous meningitis&#xD;
&#xD;
          -  Previous receipt of monomethylauristatin E (MMAE)-containing drugs&#xD;
&#xD;
          -  Pre-existing neuropathy ≥ Grade 2 per the National Cancer Institute's Common&#xD;
             Terminology Criteria for Adverse Events (NCI CTCAE) v5.0&#xD;
&#xD;
          -  Any uncontrolled ≥ Grade 3 (per the NCI CTCAE, Version 5.0) viral, bacterial, or&#xD;
             fungal infection within 2 weeks prior to the first dose of SGN-STNV&#xD;
&#xD;
        There are additional inclusion and exclusion criteria. The study center will determine if&#xD;
        criteria for participation are met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne McGoldrick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Gailloud</last_name>
      <phone>617-975-7451</phone>
    </contact>
    <investigator>
      <last_name>Gerburg Wulf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaoula Ben Haj Frej</last_name>
      <phone>617-632-6914</phone>
    </contact>
    <investigator>
      <last_name>Khanh Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth K Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Robinson</last_name>
      <phone>616-389-1739</phone>
    </contact>
    <investigator>
      <last_name>Nehal Lakhani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services Inbox</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Amita Patnaik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa / Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Laurie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arif Awan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irene Brana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Other</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Minchom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>HER2-Negative Breast Cancer</keyword>
  <keyword>High-Grade Serous Ovarian Cancer</keyword>
  <keyword>HGSOC</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>GEJ Carcinoma</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Pseudomyxoma Peritonei</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

